Primary Category:
Treatment Protocols
Disease Category:
Other
Status:
Open
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
NCT#03694002
S1701 will permanently close to accrual, effective October 15, 2022, at 12pm PT.
